ABTABBOTT LABORATORIES
Pharmaceutical Preparations
- Revenue
- $44.3B
- 5.7% YoY
- Operating margin
- 18.2%
- 12% YoY
- EBITDA
- $9.5B
- 16% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 0.6×
- $6.1B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear147% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear52% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear32% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B | 5.7% |
| Operating income | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B | 18% |
| Net income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B | 51% |
| Operating cash flow | $10.5B | $9.6B | $7.3B | $8.6B | $9.6B | 12% |
| Capex | $1.9B | $1.8B | $2.2B | $2.2B | $2.2B | 1.6% |
| Stock-based comp | $640M | $685M | $644M | $673M | $664M | 1.3% |
| Buybacks | $2.3B | $3.8B | $1.2B | $1.3B | $893M | 31% |
| Dividends | $3.2B | $3.3B | $3.6B | $3.8B | $4.1B | 7.3% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.